<![CDATA[Computational phenotyping reveals prodromal psychosis clues, connects biomarkers to symptoms, and shows why stress and cannabis reduction matters.]]>
<![CDATA[Study ties higher schizophrenia rates in Black Americans to neighborhood vulnerability, spotlighting faster early-psychosis care and social supports.]]>
Family psychoeducation to support patients with psychotic illness: two-year outcomes from a pre–post longitudinal pilot study
BackgroundPsychoeducation for families of young adults with psychosis is an evidence-based intervention that alleviates carer burden. The implementation of programming is limited, leaving family carers shouldering a heavy burden without appropriate support.ObjectiveThis pre-post longitudinal pilot study evaluated the preliminary outcomes of a psychoeducational group intervention for family carers of young adults with psychosis, aimed at building skills and reducing carer burden to support recovery in their loved ones.MethodsThe intervention, co-developed and co-facilitated by healthcare professionals and individuals with family lived experience, was delivered in Edmonton, Canada. Participants (n= 13) completed the Family Burden Interview Schedule (FBIS) at pre-intervention, post-intervention, and at 6, 12, and 24-month follow-up. Linear mixed models assessed burden scores over time.ResultsThe overall model of total burden did not reach statistical significance. Exploratory post-hoc comparisons indicated a significant total burden reduction from pre-intervention to 6-months (p = 0.032), with no other significant changes. The overall family interaction burden subscale model showed no significant effect of time. Exploratory post-hoc analyses indicated a decrease in family interaction burden from pre- to post-intervention (p = 0.026) and to 6- months (p = 0.032), with no other significant changes.ConclusionThis pilot study provides preliminary and hypothesis-generating findings suggesting a co-produced, skills- and knowledge-based psychoeducational intervention may be associated with reductions in carer burden, particularly in the domain of family relations. Given the small sample size, further research with sufficient statistical power is warranted to evaluate the long-term impact and accessibility of the intervention and inform its integration into early psychosis care.
The Download: making drugs in orbit and NASA’s nuclear-powered spacecraft
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
A plan to make drugs in orbit is going commercial
A startup called Varda Space Industries is betting that the future of pharmaceuticals lies in orbit. The company has signed a deal with United Therapeutics to test whether drugs crystallize differently in microgravity, potentially creating improved versions with new properties.
The idea sounds futuristic, but falling launch costs and reusable rockets are making space-based manufacturing seem increasingly plausible. Varda says the partnership could mark an important step toward building products in orbit for use back on Earth.
Discover how space could become the next frontier for drug development.
—Antonio Regalado
MIT Technology Review Narrated: NASA is building the first nuclear reactor-powered interplanetary spacecraft. How will it work?
Just before Artemis II began its historic slingshot around the moon, NASA revealed an even grander space travel plan. By the end of 2028, the agency aims to fly a nuclear reactor-powered interplanetary spacecraft to Mars.
A successful mission would herald a new era in spaceflight—and might just give the US the edge in the race against China. But the project remains shrouded in mystery.
MIT Technology Review picked the brains of nuclear power and propulsion experts to find out how the nuclear-powered spacecraft might work.
—Robin George Andrews
This is our latest story to be turned into an MIT Technology Review Narrated podcast, which we publish each week on Spotify and Apple Podcasts. Just navigate to MIT Technology Review Narrated on either platform, and follow us to get all our new content as it’s released.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 Sam Altman claims Elon Musk tried to seize control of OpenAI
Altman said Musk initially wanted 90% of the equity. (AFP)
+ And that control should go to his children when he dies. (BBC)
+ Altman also accused Musk of twice trying to end its non-profit status. (NPR)
+ Musk’s motivations for the suit are under scrutiny. (MIT Technology Review)
2 Google and SpaceX are in talks to launch data centers into orbit
SpaceX could join Suncatcher, Google’s orbital data center project. (WSJ $)
+ The project’s first launch is slated for early 2027. (Guardian)
+ Anthropic and SpaceX have also discussed orbital data centers. (Wired $)
+ But there are a few hurdles to overcome. (MIT Technology Review)
3 Jensen Huang has joined Donald Trump’s high-stakes mission to China
Nvidia is lobbying to sell its AI chips in the country. (Bloomberg $)
+ Elon Musk and Tim Cook are also on the trip. (CNBC)
+ But a tech rivalry and distrust have sapped hopes for big deals. (Reuters $)
4 ICE agents have a list of 20 million people on their iPhones, thanks to Palantir
An ICE official said Palantir is speeding up raids and arrests. (404 Media)
+ ICE has also used facial recognition and Paragon spyware. (TechCrunch)
5 Defense tech firm Anduril just doubled its valuation to over $60 billion
In a $5 billion funding round led by Thrive Capital and a16z. (FT $)
Anduril, which makes AI-backed weapons, may go public next year. (NYT $)
6 Meta employees are protesting computer-tracking at work
Flyers posted at offices are urging staff to oppose the program. (Reuters $)
+ Meta plans to track workers’ clicks and keystrokes to train AI. (CNBC)
7 OpenAI is facing another wrongful death lawsuit over ChatGPT medical advice
The chatbot’s tips allegedly led to a teenager’s overdose. (Ars Technica)
8 The Canvas learning platform has paid hackers to delete stolen student data
It caved to ransomware demands after the biggest-ever edtech breach. (BBC)
9 Scientific researchers are thinking twice about using AI
Due to price hikes, usage limitations, and unreliable outputs. (Nature)
10 The latest AI compute solution? Putting data centers in your home
Hardware hosts get subsidized electricity and internet. (Ars Technica)
Quote of the day
“Mr Musk did try to kill it.”
—Sam Altman claims that Elon Musk tried to destroy rather than protect OpenAI’s non-profit operations, the Guardian reports.
One More Thing
YOSHI SODEOKA
Why does AI hallucinate?
Chatbot fails are now a familiar meme. Meta’s short-lived scientific chatbot generated wiki articles about the history of bears in space. Lawyers have submitted court documents filled with legal citations fabricated by ChatGPT. Air Canada was ordered to honor a refund policy invented by its customer service chatbot.
This tendency to make things up—known as hallucination—is one of the biggest obstacles holding chatbots back from more widespread adoption. Here’s why they do it—and why we still can’t fix it.
—Will Douglas Heaven
This story is part of MIT Technology Review Explains, our series untangling the complex, messy world of technology to help you understand what’s coming next. You can read more from the series here.
We can still have nice things
A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ A historian has unearthed the etymology of every single dinosaur name.
+ Humus on the moon is getting closer to reality after scientists grew chickpeas in lunar soil.
+ Witness the patience of a master paper artist in this gallery of intricate, handmade sculptures.
+ Want to tell the time alphabetically? Me neither, but this cursed clock is an intriguing reason to try.
Direct modulation of human GABA-A α1β2γ2 receptors by the endocannabinoid 2-arachidonoylglycerol: implications for cannabinoid-related ligands and limitations for anxiolytic drug development
Anxiety disorders are associated with impaired inhibitory neurotransmission mediated by γ-aminobutyric acid type A (GABA-A) receptors. Although benzodiazepines remain effective anxiolytics, their clinical utility is limited by sedation, cognitive impairment, tolerance, and dependence, prompting the search for mechanistically distinct GABAergic modulators. Among cannabinoid-related molecules, the strongest evidence for direct GABA-A receptor modulation concerns the endocannabinoid 2-arachidonoylglycerol (2-AG), which potentiates recombinant human α1β2γ2 receptors through residues located in the M4 helix of the β2 subunit. Here, we review the structural architecture, biophysical properties, and pharmacological profile of the human GABA-A α1β2γ2 isoform as the relevant molecular framework for evaluating this mechanism, while discussing the broader relevance of cannabinoid-related ligands and selected phytocannabinoids without assuming mechanistic equivalence. We further assess the hypothesis that 2-AG reaches the β2-M4 site through a membrane-access route and identify five conceptual barriers that currently limit translation of this mechanism into anxiolytic drug development: supraphysiological effective concentrations, unresolved synaptic-versus-extrasynaptic actions, uncertain subtype selectivity, incomplete validation of lipid-environment effects, and lack of clinical evidence linking this mechanism to anxiolysis in humans. We conclude that direct modulation through β2-M4 defines a mechanistically intriguing allosteric pathway distinct from benzodiazepine action; however, its location on a shared β2 subunit and the micromolar concentrations required for modulation represent substantial obstacles to the rational design of anxioselective agents based on this mechanism.
From cats to cortex: T. gondii and psychosis, depression, and anxiety
This review examines whether cat ownership, via exposure to the neurotropic parasite T. gondii, contributes to vulnerability for psychotic, depressive, and anxiety symptoms. T. gondii establishes lifelong latent infection in the brain and muscle, where it can modulate dopaminergic signaling, neuroinflammation, and tryptophan–kynurenine metabolism, providing a biologically plausible pathway to altered cognition, mood, and behavior. Epidemiological and meta-analytic data indicate small-to-moderate associations between T. gondii seropositivity and schizophrenia, with more variable but suggestive links to depression and anxiety. Evidence for cat ownership as an independent risk factor is inconsistent: some cohorts and recent meta-analyses report elevated odds of schizophrenia-related outcomes in those exposed to cats, whereas rigorously controlled studies frequently find attenuated or null effects. Methodological limitations, alternative explanations, and cultural implications are discussed, and priorities for mechanism-informed, longitudinal and interventional research are outlined.
<![CDATA[New cohort and global data link teen high-potency cannabis use to higher psychosis, bipolar, and suicide risks. Here’s what psychiatrists and mental health clinicians should know in the era of legalization.]]>
Molecular mechanism of calcium permeability and magnesium block in NMDA receptors
Nature Neuroscience, Published online: 05 May 2026; doi:10.1038/s41593-026-02283-3
Using cryo-electron microscopy and electrophysiology, this study explains the structural basis for Ca2+ permeation and Mg2+ block in NMDA receptors and identifies a surrounding lipid network that may tune Mg2+-dependent voltage sensitivity.
<![CDATA[The FDA has approved Auvelity, an oral NMDA/sigma-1 therapy, offering a new option to curb Alzheimer disease agitation and ease caregiver burden.]]>
Functional connectivity changes in the thalamocortical network due to neck pain and the multiscale regulatory effects of acupuncture: a cross-scale multi-omics neuroimaging study
BackgroundNeck pain correlates with multiscale brain abnormalities, but cross-scale mechanisms of acupuncture analgesia are unclear. This study aimed to: (1) Explore differential modulation of thalamic functional networks by verum vs. sham acupuncture; (2) Examine associations between functional connectivity changes and micro gene expression to unravel its multiscale mechanisms.MethodsA total of 130 participants were initially enrolled, and 100 eligible neck pain patients were randomized 1:1 to the verum (n = 50) or sham (n = 50) acupuncture groups. Finally, 49 patients in each group were included for the final analysis due to one case of exclusion in each group, with treatment administered twice a week for 2 weeks. Visual Analog Scale (VAS), resting-state functional magnetic resonance imaging (fMRI), and Allen Human Brain Atlas (AHBA) transcriptome data were analyzed via Partial Least Squares (PLS) regression.ResultsBoth groups showed reduced post-treatment VAS (p < 0.001), with the verum group exhibiting a superior effect (Z = −6.877, p < 0.001). Neuroimaging revealed that verum acupuncture (VA) specifically induced significant decreases in functional connectivity (FC) between the right thalamus and left anterior cingulate cortex (T = −4.498) as well as between the right thalamus and right Rolandic operculum (T = −4.532, voxel-level p < 0.01, cluster-level p < 0.05), an effect absent in the sham acupuncture group (SA). Gene- FC association analysis indicated that PLS2 component explained 39.83% of FC variance (Pspin: permutation test p < 0.05), with weight genes showing significant spatial correlation to connectivity changes (r = 0.445, Pspin = 0.0011). A total of 809 genes were enriched in the innate immune response and phosphorylation regulation pathways, whereas 1,222 genes were enriched in the GABA-ergic synapse and synaptic membrane-related pathways.ConclusionVA relieves pain via modulating thalamus-anterior cingulate cortex networks, involving immune-inflammation and neural inhibition, providing first multi-scale validation integrating neuroimaging and transcriptomics.Clinical trial registrationThis trial was registered with the International Traditional Medicine Clinical Trial Registry (registration number: ITMCTR2023000001) prior to participant enrollment.